Management of ascites in cirrhosis

Clinics in Liver Disease

Volumn 9, Issue 4, 2005, Pages 715-732

  Sandhu, Bimaljit Singh ^a   Sanyal, Arun J ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMILORIDE; CANRENOIC ACID; DEXTRAN 70; FUROSEMIDE; LIXIVAPTAN; MIDODRINE; MINERALOCORTICOID ANTAGONIST; NIRAVOLINE; NITRIC OXIDE; NORADRENALIN; OCTREOTIDE; OPIATE; POLYGELINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPIRONOLACTONE; TERLIPRESSIN; VASOPRESSIN; VASOPRESSIN RECEPTOR ANTAGONIST;

AMMONIA FORMATION; ASCITES; ASCITES FLUID ANALYSIS; BACTERIAL PERITONITIS; COMPARATIVE STUDY; DRUG MEGADOSE; ELECTROLYTE DISTURBANCE; GYNECOMASTIA; HENLE LOOP; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMAN; HYPERKALEMIA; HYPOKALEMIA; HYPONATREMIA; ISCHEMIA; KIDNEY BLOOD FLOW; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY PERFUSION; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER TRANSPLANTATION; MALNUTRITION; NEUROLOGIC DISEASE; PARACENTESIS; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PORTOSYSTEMIC ANASTOMOSIS; QUALITY OF LIFE; RESPIRATORY DISTRESS; REVIEW; SIDE EFFECT; SODIUM RETENTION; TIME; UREMIA; VASODILATATION; WATER RETENTION;

ASCITES; DIURETICS; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PARACENTESIS; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC;

EID: 26044468526     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2005.07.008     Document Type: Review

References (89)

1. B.A. Runyon, A.A. Montano, and E.A. Akriviadis The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites Ann Intern Med 117 1992 215 220
2. P. Gines, E. Quintero, and V. Arroyo Compensated cirrhosis: natural history and prognostic factors Hepatology 7 1987 122 128
3. G. D'Amico, A. Morabito, and L. Pagliaro Survival and prognostic indicators in compensated and decompensated cirrhosis Dig Dis Sci 31 1986 468 475
4. G. Fattovich, G. Giustina, and F. Degos Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients Gastroenterology 112 1997 463 472
5. R.W. Schrier, V. Arroyo, and M. Bernardi Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis Hepatology 8 1988 1151 1157
6. P.Y. Martin, P. Gines, and R.W. Schrier Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis N Engl J Med 339 1998 533 541
7. H. Ring-Larsen, B. Hesse, and J.H. Henriksen Sympathetic nervous activity and renal and systemic hemodynamics in cirrhosis: plasma norepinephrine concentration, hepatic extraction, and renal release Hepatology 2 1982 304 310
8. G.F. DiBona Renal neural activity in hepatorenal syndrome Kidney Int 25 1984 841 853
9. V. Arroyo, R. Planas, and J. Gaya Sympathetic nervous activity, renin-angiotensin system and renal excretion of prostaglandin E2 in cirrhosis. Relationship to functional renal failure and sodium and water excretion Eur J Clin Invest 13 1983 271 278
10. V. Arroyo, P. Gines, and A.L. Gerbes Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club Hepatology 23 1996 164 176
11. K.P. Moore, F. Wong, and P. Gines The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club Hepatology 38 2003 258 266
12. B.A. Runyon Care of patients with ascites N Engl J Med 330 1994 337 342
13. B.A. Runyon Management of adult patients with ascites caused by cirrhosis Hepatology 27 1998 264 272
14. B.A. Runyon Management of adult patients with ascites due to cirrhosis Hepatology 39 2004 841 856
15. A.S. Yu, and K.Q. Hu Management of ascites Clin Liver Dis 5 2001 541 568
16. M.R. Fogel, V.K. Sawhney, and E.A. Neal Diuresis in the ascitic patient: a randomized controlled trial of three regimens J Clin Gastroenterol 3 Suppl 1 1981 73 80
17. P. Gentilini Spironolactone and canrenoate: different antialdosteronic diuretic agents Hepatology 13 1991 999 1000
18. P. Angeli, P.M. Dalla, and E. De Bei Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites Hepatology 19 1994 72 79
19. R.M. Perez-Ayuso, V. Arroyo, and R. Planas Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system Gastroenterology 84 1983 961 968
20. N. Yagi, T. Kiuchi, and H. Satoh Bioavailability and diuretic effect of furosemide following administration of tablets and retarded capsules to human subjects Biol Pharm Bull 19 1996 616 622
21. M. Bernardi, R. De Palma, and F. Trevisani Effects of a new loop diuretic (muzolimine) in cirrhosis with ascites: comparison with furosemide Hepatology 6 1986 400 405
22. P.J. Pockros, and T.B. Reynolds Rapid diuresis in patients with ascites from chronic liver disease: the importance of peripheral edema Gastroenterology 90 1986 1827 1833
23. M. Imler, R. Bockel, and B. Peter Importance of hyperammoniemia of the renal origin in the pathogenesis of hepatic coma released in cirrhotic patients by diuretics generating hypokaliemia Pathol Biol (Paris) 17 1969 5 19
24. P. Gentilini, G. Laffi, and G. La Villa Torasemide in the treatment of patients with cirrhosis and ascites Cardiovasc Drugs Ther 7 Suppl 1 1993 81 85
25. G. Laffi, F. Marra, and G. Buzzelli Comparison of the effects of torasemide and furosemide in nonazotemic cirrhotic patients with ascites: a randomized, double-blind study Hepatology 13 1991 1101 1105
26. A. Gines, G. Fernandez-Esparrach, and A. Monescillo Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis Gastroenterology 111 1996 1002 1010
27. P. Gines, L. Tito, and V. Arroyo Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis Gastroenterology 94 1988 1493 1502
28. A. Luca, J.C. Garcia-Pagan, and J. Bosch Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis Hepatology 22 1995 753 758
29. L. Ruiz-Del-Arbol, A. Monescillo, and W. Jimenez Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis Gastroenterology 113 1997 579 586
30. A. Luca, F. Feu, J.C. Garcia-Pagan, and W. Jimenez Favorable effects of total paracentesis on splanchnic hemodynamics in cirrhotic patients with tense ascites Hepatology 20 1994 30 33
31. L. Tito, P. Gines, and V. Arroyo Total paracentesis associated with intravenous albumin management of patients with cirrhosis and ascites Gastroenterology 98 1990 146 151
32. M.C. Vila, S. Coll, and R. Sola Total paracentesis in cirrhotic patients with tense ascites and dilutional hyponatremia Am J Gastroenterol 94 1999 2219 2223
33. P. Gines, V. Arroyo, and E. Quintero Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study Gastroenterology 93 1987 234 241
34. P.C. Pinto, J. Amerian, and T.B. Reynolds Large-volume paracentesis in nonedematous patients with tense ascites: its effect on intravascular volume Hepatology 8 1988 207 210
35. F. Salerno, S. Badalamenti, and P. Incerti Paracentesis: a re-evaluated procedure in the management of cirrhotic patients with ascites Ital J Gastroenterol 22 1990 44 49
36. F. Salerno, S. Badalamenti, and P. Incerti Repeated paracentesis and i.v. albumin infusion to treat 'tense' ascites in cirrhotic patients. A safe alternative therapy J Hepatol 5 1987 102 108
37. G. Fernandez-Esparrach, M. Guevara, and P. Sort Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trial of spironolactone versus placebo J Hepatol 26 1997 614 620
38. P. Gines, V. Arroyo, and V. Vargas Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites N Engl J Med 325 1991 829 835
39. P. Gines, A. Cardenas, and V. Arroyo Management of cirrhosis and ascites N Engl J Med 350 2004 1646 1654
40. P. Gentilini, V. Casini-Raggi, and G. Di Fiore Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial J Hepatol 30 1999 639 645
41. G. Laffi, P. Gentilini, and R.G. Romanelli Is the use of albumin of value in the treatment of ascites in cirrhosis? The case in favour Dig Liver Dis 35 2003 660 663
42. A.L. Gerbes, V. Gulberg, and P. Gines Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial Gastroenterology 124 2003 933 939
43. F. Wong, A.T. Blei, and L.M. Blendis A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multi-center, randomized, placebo-controlled trial Hepatology 37 2003 182 191
44. A. Gadano, R. Moreau, and F. Pessione Aquaretic effects of niravoline, a kappa-opioid agonist, in patients with cirrhosis J Hepatol 32 2000 38 42
45. C. Bureau, J.C. Garcia-Pagan, and P. Otal Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study Gastroenterology 126 2004 469 475
46. Y. Naritaka, K. Ogawa, and T. Shimakawa Clinical experience of transjugular intrahepatic portosystemic shunt (TIPS) and its effects on systemic hemodynamics Hepatogastroenterology 51 2004 1470 1472
47. J.M. Schwartz, C. Beymer, and S.J. Althaus Cardiopulmonary consequences of transjugular intrahepatic portosystemic shunts: role of increased pulmonary artery pressure J Clin Gastroenterol 38 2004 590 594
48. L.A. Colombato, L. Spahr, and J.P. Martinet Haemodynamic adaptation two months after transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients Gut 39 1996 600 604
49. A.L. Gerbes, V. Gulberg, and T. Waggershauser Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis: comparison of patients with ascites, with refractory ascites, or without ascites Hepatology 28 1998 683 688
50. W. Wong, P. Liu, and L. Blendis Long-term renal sodium handling in patients with cirrhosis treated with transjugular intrahepatic portosystemic shunts for refractory ascites Am J Med 106 1999 315 322
51. M. Rossle, V. Siegerstetter, and M. Olschewski How much reduction in portal pressure is necessary to prevent variceal rebleeding? A longitudinal study in 225 patients with transjugular intrahepatic portosystemic shunts Am J Gastroenterol 96 2001 3379 3383
52. A.M. Freedman, A.J. Sanyal, and J. Tisnado Complications of transjugular intrahepatic portosystemic shunt: a comprehensive review Radiographics 13 1993 1185 1210
53. M. Malinchoc, P.S. Kamath, and F.D. Gordon A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts Hepatology 31 2000 864 871
54. D. Patch, V. Nikolopoulou, and A. McCormick Factors related to early mortality after transjugular intrahepatic portosystemic shunt for failed endoscopic therapy in acute variceal bleeding J Hepatol 28 1998 454 460
55. E.J. Ring, J.R. Lake, and J.P. Roberts Using transjugular intrahepatic portosystemic shunts to control variceal bleeding before liver transplantation Ann Intern Med 116 1992 304 309
56. J.M. LaBerge, K.A. Somberg, and J.R. Lake Two-year outcome following transjugular intrahepatic portosystemic shunt for variceal bleeding: results in 90 patients Gastroenterology 108 1995 1143 1151
57. A.J. Sanyal, A.M. Freedman, and M.L. Shiffman Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study Hepatology 20 1994 46 55
58. K.A. Somberg, J.L. Riegler, and J.M. LaBerge Hepatic encephalopathy after transjugular intrahepatic portosystemic shunts: incidence and risk factors Am J Gastroenterol 90 1995 549 555
59. P.A. McCormick, R. Dick, and E.B. Panagou Emergency transjugular intrahepatic portasystemic stent shunting as salvage treatment for uncontrolled variceal bleeding Br J Surg 81 1994 1324 1327
60. P.S. Kamath, R.H. Wiesner, and M. Malinchoc A model to predict survival in patients with end-stage liver disease Hepatology 33 2001 464 470
61. P. Pare, J. Talbot, and J.C. Hoefs Serum-ascites albumin concentration gradient: a physiologic approach to the differential diagnosis of ascites Gastroenterology 85 1983 240 244
62. W.G. Rector Jr, and T.B. Reynolds Superiority of the serum-ascites albumin difference over the ascites total protein concentration in separation of transudative and exudative ascites Am J Med 77 1984 83 85
63. P. Gines, T. Berl, and M. Bernardi Hyponatremia in cirrhosis: from pathogenesis to treatment Hepatology 28 1998 851 864
64. J. Santos, R. Planas, and A. Pardo Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety J Hepatol 39 2003 187 192
65. L. Shear, S. Ching, and G.J. Gabuzda Compartmentalization of ascites and edema in patients with hepatic cirrhosis N Engl J Med 282 1970 1391 1396
66. D.M. Heuman, S.G. Abou-Assi, and A. Habib Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death Hepatology 40 2004 802 810
67. A. Porcel, F. Diaz, and P. Rendon Dilutional hyponatremia in patients with cirrhosis and ascites Arch Intern Med 162 2002 323 328
68. P. Gines, J. Uriz, and B. Calahorra Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis Gastroenterology 123 2002 1839 1847
69. A. Ochs, M. Rossle, and K. Haag The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites N Engl J Med 332 1995 1192 1197
70. K.M. Peltekian, F. Wong, and P.P. Liu Cardiovascular, renal, and neurohumoral responses to single large-volume paracentesis in patients with cirrhosis and diuretic-resistant ascites Am J Gastroenterol 92 1997 394 399
71. M.L. Shiffman, L. Jeffers, and J.H. Hoofnagle The role of transjugular intrahepatic portosystemic shunt for treatment of portal hypertension and its complications: a conference sponsored by the National Digestive Diseases Advisory Board Hepatology 22 1995 1591 1597
72. M. Rossle, A. Ochs, and V. Gulberg A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites N Engl J Med 342 2000 1701 1707
73. A.J. Sanyal, C. Genning, and K.R. Reddy The North American Study for the Treatment of Refractory Ascites Gastroenterology 124 2003 634 641
74. M. Epstein, D.P. Berk, and N.K. Hollenberg Renal failure in the patient with cirrhosis. The role of active vasoconstriction Am J Med 49 1970 175 185
75. E. Akriviadis, R. Botla, and W. Briggs Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial Gastroenterology 119 2000 1637 1648
76. P. Angeli, R. Volpin, and G. Gerunda Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide Hepatology 29 1999 1690 1697
77. C. Duvoux, D. Zanditenas, and C. Hezode Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study Hepatology 36 2002 374 380
78. R. Moreau, F. Durand, and T. Poynard Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study Gastroenterology 122 2002 923 930
79. R. Ortega, P. Gines, and J. Uriz Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study Hepatology 36 2002 941 948
80. G. Pomier-Layrargues, S.C. Paquin, and Z. Hassoun Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, cross-over study Hepatology 38 2003 238 243
81. J. Uriz, P. Gines, and A. Cardenas Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome J Hepatol 33 2000 43 48
82. S. Nair, S. Verma, and P.J. Thuluvath Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation Hepatology 35 2002 1179 1185
83. P. Gines, M. Guevara, and F. Perez-Villa Management of hepatorenal syndrome: another piece of the puzzle Hepatology 40 2004 16 18
84. V. Gulberg, and A.L. Gerbes TIPS or vasoconstrictors for the treatment of hepatorenal syndrome type 1-effect on survival? Z Gastroenterol 40 2002 823 826
85. T.M. Sturgis Hepatorenal syndrome: resolution after transjugular intrahepatic portosystemic shunt J Clin Gastroenterol 20 1995 241 243
86. F. Wong Transjugular intrahepatic portosystemic stent shunt for hepatorenal syndrome and ascites Digestion 59 Suppl 2 1998 41 44
87. F. Wong, L. Pantea, and K. Sniderman Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome Hepatology 40 2004 55 64
88. A. Rimola, G. Garcia-Tsao, and M. Navasa Diagnosis, treatment, and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club J Hepatol 32 2000 142 153
89. A. Follo, J.M. Llovet, and M. Navasa Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis Hepatology 20 1994 1495 1501